In A BIND And Short On Cash
This article was originally published in Scrip
Executive Summary
You may also be interested in...
Pfizer Jumps At The Chance To Apply Bind’s Technology To Immuno-Oncology
Bind has agreed to sell all of its assets to Pfizer for $19.75m after filing for bankruptcy in May. An auction is scheduled for July 25 if other bidders come forward.
Biotech Bankruptcies: BIND and NephroGenex Weigh Options
Once-prosperous biotechs are now seeking strategic alternatives including the selling off of all of their assets now that they've failed to acquire the funds they need to move forward.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.